AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KIDS

Pritzker Jennifer N. sold $525K of KIDS (indirect holdings)

Pritzker Jennifer N. sold 22,500 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at $23.35 ($0.53M total) on 2026-09-02.

Original reporting
SEC EDGAR · Pritzker Jennifer N.
Published Sep 4, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KIDS
Neutral
medium confidence
Mentioned
$KIDS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KIDSNeutralLow
01

Why it matters

The disclosed sale is the first public report of this insider transaction, providing new data for traders.

02

Market read

New insider sale adds modest negative sentiment but limited trading impact.

03

What to watch

Potential upcoming regulatory or product developments not disclosed.

Relevance 5/10Novelty 4/10Timing: today

Background

SEC Form 4 filing reports insider transaction for Orthopedics Corp (KIDS).

Company-level read

Ticker impact

$KIDSNeutralMedium confidence
Context

Form 4 disclosed Jennifer N. Pritzker sold 22,500 shares of Orthopedics Corp for $525,375.

Expected impact

Potential slight downward pressure, likely limited.

Evidence & confidence

Sale represents ~0.35% of post‑transaction holdings; market may view as routine.

Market effects

Sector

Minimal impact on orthopedics sector; insider activity is routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could be a pre‑emptive move before negative news, suggesting caution.

Key entities

  • Insider
    Jennifer N. Pritzker

    10% owner of Orthopedics Corp.

  • Company
    Orthopedics Corp

    Ticker KIDS, medical device manufacturer.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KIDS insider trading history →

Related articles

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

rttnews.com
$KIDSMed

OrthoPediatrics Corp (KIDS) (Q3 2026) Earnings Call Highlights: Record Revenue and Raised Guidance

OrthoPediatrics Corp (KIDS) reported Q3 2026 revenue growth and raised guidance, despite increased sales expenses and gross margin pressure. The company expects Q4 revenue of roughly $69 million, with CEO David Bailey noting a conservative approach to guidance. International growth was tempered by Brazil headwinds, and the company remains unprofitable with a GAAP net loss per share of $0.25.

finance.yahoo.com
$KIDSMed

OrthoPediatrics Q3 Earnings Call Highlights

OrthoPediatrics (KIDS) reported Q3 revenue growth, with scoliosis revenue up 18% to $19.2M. The company surpassed 1,000 PNP tibial nail implantations and plans a full commercial release for PNP Retrograde in mid-2027. OPSB segment grew over 20%, with 60+ clinics. Gross margin remained at 74%, while GAAP net loss narrowed to $0.25 per share. The company raised full-year 2026 revenue guidance to $270M-$273M and expects positive free cash flow in 2027.

finance.yahoo.com
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Q3 2026 Earnings Call Transcript

OrthoPediatrics (KIDS) reported Q3 2026 revenue of $727M, up 19% YoY, and raised full-year guidance to $270M-$273M. Growth was driven by legacy products, implant demand, and international sales. The company highlighted progress in its innovation super cycle, with new products like 3P Hip, Traxeo, and VerteGlide contributing to performance. Adjusted EBITDA and free cash flow were record highs, with plans to maintain positive cash flow in 2027.

finance.yahoo.com